Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer

NCT ID: NCT03877796Sponsor: Allarity TherapeuticsLast updated: 2025-10-30

Summary

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Arms & interventions

  • DeviceDrug Response Predictor® (DRP)

    A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Outcome measures

Primary

  • Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug

    based on FFPE ovarian cancer tissue

    Time frame: up to 2 years

Secondary

  • Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer

    Time frame: up to 2 years

Eligibility criteria

Sex: FemaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Patients with histological confirmed epithelia ovarian cancer * Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. * Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting * FFPE tumor tissue available Exclusion Criteria: * Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. * Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

Study locations (3)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Completed

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104

Recruiting
Christine Pappaterra, RN · Contact
405-271-8707Christine-Pappaterra@ouhsc.edu
Kathleen Moore, MD · Principal Investigator

Swedish Center for Research and Innovation

Seattle, Washington, 98122

Recruiting
Karina Sills · Contact
206-386-2227karina.sills@swedish.org
Fernanda Baptista Musa, MD · Principal Investigator